Vestmark Advisory Solutions Inc. grew its stake in shares of Eli Lilly And Co (NYSE:LLY) by 22.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 11,922 shares of the company’s stock after purchasing an additional 2,216 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Eli Lilly And Co were worth $1,333,000 as of its most recent SEC filing.
Several other large investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC bought a new position in shares of Eli Lilly And Co during the third quarter valued at approximately $1,431,000. Motco grew its holdings in Eli Lilly And Co by 10.8% in the 3rd quarter. Motco now owns 51,242 shares of the company’s stock worth $5,730,000 after buying an additional 5,009 shares in the last quarter. Carillon Tower Advisers Inc. grew its holdings in Eli Lilly And Co by 685.1% in the 3rd quarter. Carillon Tower Advisers Inc. now owns 166,439 shares of the company’s stock worth $18,613,000 after buying an additional 145,239 shares in the last quarter. Principle Wealth Partners LLC bought a new position in Eli Lilly And Co in the 3rd quarter worth approximately $275,000. Finally, Sector Gamma AS bought a new position in Eli Lilly And Co in the 3rd quarter worth approximately $17,010,000. 77.37% of the stock is owned by institutional investors.
NYSE LLY traded up $0.37 on Tuesday, reaching $113.17. 2,229,901 shares of the stock traded hands, compared to its average volume of 7,631,578. The firm’s fifty day simple moving average is $110.45 and its 200 day simple moving average is $112.63. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09. The company has a market cap of $109.00 billion, a price-to-earnings ratio of 20.39, a P/E/G ratio of 1.86 and a beta of 0.16. Eli Lilly And Co has a 12 month low of $101.36 and a 12 month high of $132.13.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a yield of 2.28%. The ex-dividend date of this dividend is Thursday, November 14th. Eli Lilly And Co’s payout ratio is currently 46.49%.
A number of equities analysts recently issued reports on the company. UBS Group decreased their price objective on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a report on Thursday, October 17th. TheStreet raised Eli Lilly And Co from a “c+” rating to a “b-” rating in a report on Friday. Finally, Bank of America assumed coverage on Eli Lilly And Co in a report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price objective for the company. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $130.03.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 173,918 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $114.05, for a total transaction of $19,835,347.90. Following the completion of the transaction, the insider now directly owns 116,229,383 shares of the company’s stock, valued at approximately $13,255,961,131.15. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $112.91, for a total value of $2,201,745.00. Following the transaction, the senior vice president now directly owns 38,306 shares of the company’s stock, valued at $4,325,130.46. The disclosure for this sale can be found here. Over the last ninety days, insiders have acquired 8,405 shares of company stock valued at $909,004 and have sold 614,473 shares valued at $70,558,302. Company insiders own 0.11% of the company’s stock.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Read More: What is a dividend reinvestment plan?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.